Host cell protein testing by ELISAs and the use of orthogonal methods

Biotechnology and Bioengineering

Volumn 111, Issue 12, 2014, Pages 2367-2379

  Zhu Shimoni, Judith ^a   Yu, Christopher ^a   Nishihara, Julie ^a   Wong, Robert M ^a   Gunawan, Feny ^a   Lin, Margaret ^a   Krawitz, Denise ^a   Liu, Peter ^a   Sandoval, Wendy ^a   Vanderlaan, Martin ^a  

^a GENENTECH INC   (United States)

Author keywords

Antigen excess; ELISA; Host cell proteins; Linearity; Multi analyte; Orthogonal methods

Indexed keywords

ANTIBODIES; EPITOPES; MASS SPECTROMETRY; RISK ASSESSMENT;

ELISA; HOST CELL PROTEIN; LINEARITY; MULTI-ANALYTES; ORTHOGONAL METHOD;

RECOMBINANT PROTEINS;

HOST CELL PROTEIN; HOST CELL PROTEIN ANTIBODY; PROTEIN ANTIBODY; REAGENT; RECOMBINANT ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; PROTEIN;

ANTIGEN ANTIBODY COMPLEX; CASE STUDY; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HOST CELL; HUMAN; IMMUNOREACTIVITY; MASS SPECTROMETRY; NONHUMAN; NONLINEAR SYSTEM; PROCESS DEVELOPMENT; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; REVIEW; RISK ASSESSMENT; ANIMAL; BIOTECHNOLOGY; CHEMISTRY; CHO CELL LINE; CRICETULUS; HAMSTER; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PROCEDURES; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ANTIBODIES; BIOTECHNOLOGY; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; PROTEINS; RECOMBINANT PROTEINS; RESEARCH DESIGN;

EID: 84918578190     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25327     Document Type: Review

References (41)

1. Anicetti VR, Fehskens EF, Reed BR, Chen AB, Moore P, Geier MD, Jones AJ. 1986. Immunoassay for the detection of E. coli proteins in recombinant DNA derived human growth hormone. J Immunol Methods 91(2):213-224.
2. Blattner FR, Plunkett G III, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y. 1997. The complete genome sequence of Escherichia coli K-12. Science 277(5331):1453-1462.
3. Bomans K, Lang A, Roedl V, Adolf L, Kyriosoglou K, Diepold K, Eberl G, Molhoj M, Strauss U, Schmalz C, Vogel R, Reusch D, Wegele H, Wiedmann M, Bulau P. 2013. Identification and monitoring of host cell proteins by mass spectrometry combined with high performance immunochemistry testing. PLoS ONE 8(11):e81639.
4. Bosmann M, Kossler J, Stolz H, Walter U, Knop S, Steigerwald U. 2010. Detection of serum free light chains: The problem with antigen excess. Clin Chem Lab Med 48(10):1419-1422.
5. Brinks V, Jiskoot W, Schellekens H. 2011. Immunogenicity of therapeutic proteins: The use of animal models. Pharm Res 28(10):2379-2385.
6. Champion K, Madden H, Dougherty J, Shacter E. 2005. Defining your product profile and maintaining control over it, part 2. Bioprocess Int (September 2005): 52-57.
7. Code of Federal Regulations Title 21 Food and Drugs Parts 600 to 799. April 1st. 2013 Edition ed: Office of the Federal Register National Archives and Records Administration.
8. Champion KM, Nishihara JC, Joly JC, Arnott D. 2001. Similarity of the Escherichia coli proteome upon completion of different biopharmaceutical fermentation processes. Proteomics 1(9):1133-1148.
9. Daval S, Tridon A, Mazeron N, Ristori JM, Evrard B. 2007. Risk of antigen excess in serum free light chain measurements. Clin Chem 53(11):1985-1986.
10. Doneanu CE, Xenopoulos A, Fadgen K, Murphy J, Skilton SJ, Prentice H, Stapels M, Chen W. 2012. Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry. MAbs 4(1):24-44.
11. Eaton LC. 1995. Host cell contaminant protein assay development for recombinant biopharmaceuticals. J Chromatogr A 705(1):105-114.
12. EMA. 2006. Omnitrope, European Public Assessment Report, April 2006.
13. Gagnon P, Hensel F, Lee S, Zaidi S. 2011a. Chromatographic behavior of IgM:DNA complexes. J Chromatogr A 1218(17):2405-2412.
14. Gagnon P, Rodriquez G, Zaidi S. 2011b. Dissociation and fractionation of heavy and light chains from IgG monoclonal antibodies. J Chromatogr A 1218(17):2402-2404.
15. Gao SX, Zhang Y, Stansberry-Perkins K, Buko A, Bai S, Nguyen V, Brader ML. 2011. Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. Biotechnol Bioeng 108(4):977-982.
16. Jenner E, Levoguer A, Evans J, Harding S. 2012. Serum free light chain immunoassays: A guide to antigen excess detection. Clin Chim Acta 413(9-10):949 author reply 952.
17. Jones AJ. 1988. Sensitive detection and quantitation of protein contaminants in rDNA products. In: Phillips M, editor. In the impact of chemistry on biotechnology. 1990/01/01 ed: American Chemical Society, p 193-201.
18. Krawitz DC, Forrest W, Moreno GT, Kittleson J, Champion KM. 2006. Proteomic studies support the use of multi-product immunoassays to monitor host cell protein impurities. Proteomics 6(1):94-110.
19. Lewis NE, Liu X, Li Y, Nagarajan H, Yerganian G, O'Brien E, Bordbar A, Roth AM, Rosenbloom J, Bian C, Xie M, Chen W, Li N, Baycin-Hizal D, Latif H, Forster J, Betenbaugh MJ, Famili I, Xu X, Wang J, Palsson BO. 2013. Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome. Nat Biotechnol 31(8):759-765.
20. Lopez MF, Berggren K, Chernokalskaya E, Lazarev A, Robinson M, Patton WF. 2000. A comparison of silver stain and SYPRO Ruby Protein Gel Stain with respect to protein detection in two-dimensional gels and identification by peptide mass profiling. Electrophoresis 21(17):3673-3683.
21. Luhrs KA, Harris DA, Summers S, Parseghian MH. 2009. Evicting hitchhiker antigens from purified antibodies. J Chromatogr B Analyt Technol Biomed Life Sci 877(14-15):1543-1552.
22. Mechetner L, Sood R, Nguyen V, Gagnon P, Parseghian MH. 2011. The effects of hitchhiker antigens co-eluting with affinity-purified research antibodies. J Chromatogr B Analyt Technol Biomed Life Sci 879(25):2583-2594.
23. Nishihara JC, Champion KM. 2002. Quantitative evaluation of proteins in one- and two-dimensional polyacrylamide gels using a fluorescent stain. Electrophoresis 23(14):2203-2215.
24. Quarmby V, tawde SA, Richards S. 2012. Immunogenicity: A critical issue in biotherapeutic development. AAPS NEWSMAGAZINE (May12) 24-27.
25. Rey G, Wendeler MW. 2012. Full automation and validation of a flexible ELISA platform for host cell protein and protein A impurity detection in biopharmaceuticals. J Pharm Biomed Anal 70:580-586.
26. Saenger P. 2009. Current status of biosimilar growth hormone. Int J Pediatr Endocrinol 2009:370329.
27. Sandberg H, Lutkemeyer D, Kuprin S, Wrangel M, Almstedt A, Persson P, Ek V, Mikaelsson M. 2006. Mapping and partial characterization of proteases expressed by a CHO production cell line. Biotechnol Bioeng 95(5):961-971.
28. Schenauer MR, Flynn GC, Goetze AM. 2012. Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry. Anal Biochem 428(2):150-157.
29. Sharma B. 2007. Immunogenicity of therapeutic proteins. Part 2: Impact of container closures. Biotechnol Adv 25(3):318-324.
30. Shukla AA, Hinckley P. 2008. Host cell protein clearance during protein A chromatography: Development of an improved column wash step. Biotechnol Prog 24(5):1115-1121.
31. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies-Application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 848(1):28-39.
32. Sisodiya VN, Lequieu J, Rodriguez M, McDonald P, Lazzareschi KP. 2012. Studying host cell protein interactions with monoclonal antibodies using high throughput protein A chromatography. Biotechnol J 7(10):1233-1241.
33. Tait AS, Hogwood CE, Smales CM, Bracewell DG. 2012. Host cell protein dynamics in the supernatant of a mAb producing CHO cell line. Biotechnol Bioeng 109(4):971-982.
34. Thakrar K, bodalia P, Grosso A. 2010. Assessing the efficacy and safety of Omnitrope. Br J Clin Pharm 2:298-301.
35. Van Cleave VH. 2003. Vailidation of immunoassays for anti-drug antibodies. Dev Biol (Basel) 112:107-112.
36. Wang W, Ignatius AA, Thakkar SV. 2014. Impact of residual impurities and contaminants on protein stability. J Pharm Sci 103(5):1315-1330.
37. Wang X, Hunter AK, Mozier NM. 2009. Host cell proteins in biologics development: Identification, quantitation and risk assessment. Biotechnol Bioeng 103(3):446-458.
38. Xu X, Nagarajan H, Lewis NE, Pan S, Cai Z, Liu X, Chen W, Xie M, Wang W, Hammond S, Andersen MR, Neff N, Passarelli B, Koh W, Fan HC, Wang J, Gui Y, Lee KH, Betenbaugh MJ, Quake SR, Famili I, Palsson BO. 2011. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat Biotechnol 29(8):735-741.
39. Xue L, Johnson R, Gorovits B. 2010. Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serum. AAPS J 12(1):98-106.
40. Zhang Q, Goetze AM, Cui H, Wylie J, Trimble S, Hewig A, Flynn GC. 2014. Comprehensive tracking of host cell proteins during monoclonal antibody purifications using mass spectrometry. MAbs 6(3):659-670.
41. Zhu G, Sun L, Wojcik R, Kernaghan D, McGivney JB, Dovichi NJ. 2012. A rapid cIEF-ESI-MS/MS method for host cell protein analysis of a recombinant human monoclonal antibody. Talanta 98:253-256.